Triple therapy for obese patients with type 2 diabetes: evaluating effectiveness of the metformin + exenatide + glibenclamide combination

Abstract

The questions of phased management of metabolic disorders in patients with type 2 diabetes with obesity are considered. The advantages of various triple therapy regimens depending on the objectives and key pathogenic defects are demonstrated. Results of a clinical trial substantiating different treatment options are provided. The benefits of triple therapy consisting of metformin, glyburide (micronized), exenatide are evaluated.